Compare Redwire Corporation (RDW) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Twist Bioscience Corp — how do they compare? Redwire Corporation trades at $9.02 (market cap $2.25B), while Twist Bioscience Corp trades at $93.82 (market cap $5.97B). The key difference: Twist Bioscience Corp is far larger — about 2.7× Redwire Corporation's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| RDW | TWST | |
|---|---|---|
Market Cap | $2.25B | $5.97B |
Sector | Technology | Health |
52-Week High | $25.90 | $102.88 |
52-Week Low | $5.06 | $24.16 |
Enterprise Value | $2.31B | $5.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire (RDW) trades at $8.60, down 1.78% with a bearish technical signal despite oversold RSI readings. The company shows strong revenue growth potential with a record $492 million backlog and a 1.92 book-to-bill ratio, but faces significant profitability challenges with a net income margin of -80.9% and consecutive earnings misses. Recent expansions in Indiana and Alabama highlight operational growth amid substantial cash burn from operations.
The stock presents a high-risk, high-reward opportunity with an 80% analyst buy rating and a $19.00 consensus price target implying over 120% upside. However, persistent losses, negative cash flow from operations, and potential dilution from a $500 million ATM offering pose substantial risks to near-term shareholder value.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
